首页> 外文期刊>BMC Medical Imaging >The prevention of anaphylactoid reactions to iodinated radiological contrast media: a systematic review
【24h】

The prevention of anaphylactoid reactions to iodinated radiological contrast media: a systematic review

机译:预防对碘化造影剂的类过敏反应:系统评价

获取原文
       

摘要

Background Anaphylactoid reactions to iodinated contrast media are relatively common and potentially life threatening. Opinion is divided as to the utility of medications for preventing these reactions. We performed a systematic review to assess regimes for the prevention of anaphylactoid reactions to iodinated contrast media. Methods Searches for studies were conducted in the Medline, EMBASE, CINAHL and CENTRAL databases. Bibliographies of included studies and review articles were examined and experts were contacted. Randomised clinical trials that examined agents given prior to iodinated contrast material for the prevention of anaphylactoid reactions were included in the review. The validity of the included studies was examined using a component approach. Results Six studies met the inclusion criteria, but only one of these fulfilled all of the validity criteria. There were four studies that examined the use of H1 antihistamines, each was used to prevent anaphylactoid reactions to ionic contrast. The random effects pooled relative risk demonstrated a significant reduction in the overall rate of anaphylactoid reactions (RR = 0.4, 95% CI 0.18-0.9, p = 0.027). There were insufficient studies to produce a pooled statistic for the use of corticosteroids, however regimes of steroids (methylprednisolone 32 mg) given at least six hours and again two hours prior to the administration of contrast suggested a reduction in the incidence of anaphylactoid reactions. Conclusion In conclusion, there are few high quality randomised clinical trials that have addressed the question of the optimal methods to prevent allergic type reactions to iodinated radiological contrast media. Allowing for these limitations, the results suggest that H1 antihistamines given immediately prior to the administration of ionic contrast may be useful in preventing reactions to ionic contrast and are suggestive of a protective effect of corticosteroids when given in two doses at least six hours prior and again two hours prior to the administration of contrast, both ionic and non-ionic. These agents should be considered for use in patients who are at high risk of an anaphylactoid reaction to contrast media and for who prophylactic therapy is considered necessary. Further research is needed before definitive recommendations can be made.
机译:背景技术对碘化造影剂的类过敏反应相对普遍,并且可能危及生命。关于药物用于预防这些反应的观点存在分歧。我们进行了系统的评估,以评估预防对碘化造影剂类过敏反应的方案。方法在Medline,EMBASE,CINAHL和CENTRAL数据库中进行研究搜索。研究了纳入研究和评论文章的书目并联系了专家。该评价包括随机临床试验,该试验检查了在碘化造影剂之前给予的药物以预防类过敏反应。纳入研究的有效性使用成分分析法进行了检验。结果6项研究符合纳入标准,但只有一项符合所有有效性标准。有四项研究检查了H1抗组胺药的使用,每项研究均用于预防类过敏反应对离子造影剂的影响。汇总相对危险度的随机效应表明类过敏反应的总体发生率显着降低(RR = 0.4,95%CI 0.18-0.9,p = 0.027)。尚无足够的研究得出使用皮质类固醇激素的综合统计数据,但是在给予对比剂前至少六个小时和两个小时再给予类固醇激素(甲基泼尼松龙32毫克)提示类过敏反应的发生率降低。结论总之,很少有高质量的随机临床试验解决了预防对碘化造影剂过敏性反应的最佳方法的问题。考虑到这些局限性,结果表明,在立即施用离子对比剂之前给予H1抗组胺药可能有助于预防对离子对比剂的反应,并且提示在两次注射前至少六小时再两次给予皮质类固醇激素具有保护作用。对比剂(离子性和非离子性)给药前两个小时。这些药物应考虑用于对造影剂有过敏性反应的高风险且认为必须进行预防性治疗的患者。在做出明确的建议之前,需要进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号